We examined the effect of nicardipine and hyperventilatin on pulmonary arterial pressure (PAP) in four patients with pulmonary hypertension in congenital heart defect especially in the early postoperative period. There was a significant positive correlation between the values of arterial carbon dioxide tension (PaCO2) and the ratio of mean PAP to mean systemic arterial pressure (Pp/Ps) in two patients whose Heath Edwards classification was Grade II; one of them also had 20% reduction of mean PAP by nicardipine without changing mean arterial pressure. In the remaining two patients showing no correlation between the values of PaCO2 and Pp/Ps, nicardipine did not reduce PAP. Although nicardipine reduced PAP without changing systemic arterial pressure in only one out of four patients, these results suggest that nicardipine may be a drug for control of PAP during weaning phase from the ventilator especially in patients whose PAP decreases under hyperventilation.
Using the physiological salt solution (PSS)/Ficollperfused rat lung, we studied the effect of prostaglandin I (PGI) analogue, OP-2507, on ischemia-reperfusion lung injury. Ischemia was induced by stopping perfusion and ventilation. Reperfusion after 90 min of normothermic ischemia increased mean pulmonary artery perfusion pressure (Ppa) and produced significant lung edema. Pretreatment with OP-2507 (200 ng·ml and 1000 ng·ml) equally attenuated the increase in Ppa and lung edema after reperfusion. Lactate dehydrogenase release from the OP-2507-treated lungs of both doses were significantly lower than the untreated lungs. Thus, OP-2507 seems to be a useful agent for preventing ischemia-reperfusion lung injury.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.